BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM
EXECUTIVE COMMITTEE

Wednesday, September 1, 2021
11:00 a.m.

To be held by video/telephone conference

AGENDA

1. Calling of the roll

2. Declaration of conflicts

3. Approval of UW-Madison Contractual Agreement with WISC Partners GP II LLC

4. Approval of UW-Madison Contractual Agreement with Regeneron Pharmaceuticals, Inc.

5. Move into closed session to consider an amended additional compensation agreement for the UW-Madison head football coach, as permitted by s. 19.85(1)(c) and (e), Wis. Stats.

6. Adjourn

Webex videoconference registration information and meeting materials can be found at https://www.wisconsin.edu/regents/meetingmaterials or may be obtained from Jess Lathrop, Executive Director, Office of the Board of Regents, 1860 Van Hise Hall, 1220 Linden Drive, Madison, WI 53706, (608) 262-2324.
Executive Committee
September 1, 2021

Item 3.

UW-MADISON CONTRACTUAL AGREEMENT
WITH WISC PARTNERS GP II LLC

REQUESTED ACTION

Adoption of Resolution 3., approving the contractual agreement between the Board of Regents and WISC Partners GP II LLC.

Resolution 3. That, upon recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and WISC Partners GP II LLC.

SUMMARY

This Agreement provides funding to the College of Engineering for consulting services, administrative costs, and potential profit sharing from the sale of WISC Partners portfolio companies. The agreement establishes payments from three activities. These are:

1. Administration and management work with WISC Partners to identify possible needs for emerging companies ($10,000/month);
2. Provision of technical services to emerging companies (variable depending on services); and
3. Revenue sharing to UW-Madison when portfolio companies of WISC Partners are sold off to the new owner (5 – 10% depending on services involved).

Presenter:

- Rob Cramer, Interim Vice Chancellor for Finance and Administration, UW-Madison

BACKGROUND

The aim of WISC Partners is to help emerging companies get started. To date, this is primarily done this through venture funds. However, a major roadblock for emerging
companies is not necessarily finances but a lack of infrastructure to navigate problems that develop as the company tries to get started. Through this agreement, UW-Madison will collaborate with WISC Partners to provide technical engineering services to these emerging companies. In doing so, UW-Madison will make valuable connections with new companies emerging in the local community, helping to enhance the State of Wisconsin’s economic health as well as UW-Madison’s corporate engagement.

UW-Madison is committed to working with Wisconsin firms to strengthen them and increase their competitiveness. Engaging with WISC Partners in this manner supports the mission of the institution. This agreement aligns with the Revenue Innovations work of UW-Madison and the strategy of corporate and industry partnerships. The partnership will leverage the capabilities of faculty in the College of Engineering, will lead to mutually beneficial outcomes, and will build on current successes. The revenue generated through this partnership will provide the college with much needed resources to hire new faculty (the cost of launching the career of a new faculty member is between $600,000 and $1,000,000 per hire) and to maintain state-of-the-art facilities that benefit both the instructional and research missions of the college. These funds will ensure the college remains on the cutting edge of teaching innovation, providing students financial resources, learning experiences and academic support.

This is UW-Madison’s first agreement with WISC Partners GP LLC.

Regent Policy Document 13-1 requires any grant or contract with private, profit-making organizations in excess of $1,000,000 be presented to the Board of Regents for formal approval prior to execution.

**Related Policies**

- Regent Policy Document 13-1, “General Contract Signature Authority, Approval, and Reporting”
REQUESTED ACTION

Adoption of Resolution 4., approve the contractual agreement between the Board of Regents and Regeneron Pharmaceuticals, Inc.

Resolution 4. That, upon recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and Regeneron Pharmaceuticals, Inc.

SUMMARY

This Agreement allows the parties to work collaboratively in order to conduct a clinical study which requires the use of a Regeneron Product (defined herein) under a protocol entitled: “Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescent (CAUSE01 / PANDA)”.  

The National Institute of Allergy and Infectious Disease (NIAID), not Regeneron, is the protocol sponsor for this study. Regeneron and NIAID have a clinical trial agreement that, in part, provides the funding for this work.

Presenter:

• Rob Cramer, Interim Vice Chancellor for Finance and Administration, UW-Madison

BACKGROUND

Regeneron Pharmaceuticals, Inc. is an American pharmaceutical company founded in 1988 by a team of physician-scientists. Specializing in antibody medicines, Regeneron invents and researches potential new medicines for a broad range of serious conditions, including retinal eye diseases, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. Their industry-leading antibody technologies and scientific teams
enable them to identify and study dozens of potential drug candidates simultaneously and with great efficiency. The best of these candidates then progress into thorough preclinical and clinical research phases, building their portfolio of over 30 investigational medicines.

This is a nation-wide study. UW-Madison will be the primary site and will have nine sub-sites (listed in Exhibit C of the agreement) performing the study or providing other specialized support services (for example, sample processing). The sites were selected because they all have premier asthma research programs and are spread out across the country.

Over the past five years, UW has executed 22 research or clinical trial agreements with Regeneron. The total received from Regeneron for those 22 agreements was approximately $4.7 million.

Regent Policy Document 13-1 requires any grant or contract with private, profit-making organizations in excess of $1,000,000 be presented to the Board of Regents for formal approval prior to execution.

**Related Policies**

- Regent Policy Document 13-1, “General Contract Signature Authority, Approval, and Reporting”